FGFR1 and neoplasm: Contrary to previous clinical trials that used FGFR1 amplification, a genetic change that occurs in ~17% of human LUSC (cBioPortal, TCGA PanCancer Atlas), as a predictor of inhibitor response, PDX responses demonstrated that high FGFR1 RNA levels instead were indicative of FGFR inhibitor-induced tumour cell differentiation and enhanced tumour cell death, particularly when combined with cisplatin99.